SNDX Syndax Pharmaceuticals Inc: institutional ownership and insider trading
254 funds reported holding $2.51B of Syndax Pharmaceuticals Inc in their latest 13F filings; in Q2 2026 funds net bought $187M, with 34 new positions and 39 funds selling out; over the last 12 months insiders bought $0 and sold $2.75M on the open market; over its last four quarters it reported revenue of $252M and net income of −$221M.
SNDX revenue and earnings
- Quarter ended Jun 30, 2026: revenue $72.8M, net income −$49.4M, EPS -0.55
- Quarter ended Mar 31, 2026: revenue $64.9M, net income −$42.7M, EPS -0.48
- Quarter ended Dec 31, 2025: revenue $68.5M, net income −$68.0M, EPS -0.78
- Quarter ended Sep 30, 2025: revenue $45.9M, net income −$60.7M, EPS -0.70
Famous investors holding SNDX
- Izzy Englander (Millennium Management): $44.9M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $34.5M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $27.1M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $7.03M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $7.54M, 0.0% of the portfolio
Largest institutional holders of SNDX
- BlackRock, Inc. (BLK) — $197M
- Kynam Capital Management, LP — $176M
- VANGUARD GROUP INC — $131M
- GOLDMAN SACHS GROUP INC (GS, GSCE, GS-PA, GS-PC, GS-PD) — $128M
- STATE STREET CORP (STT, STT-PG) — $124M
- BANK OF AMERICA CORP /DE/ (BAC, BAC-PB, BAC-PE, BAC-PK, BAC-PL, BAC-PM, BAC-PN, BAC-PO, BAC-PP, BML-PG, BML-PH, BML-PJ, BML-PL) — $88.4M
- VANGUARD CAPITAL MANAGEMENT LLC — $85.9M
- DEERFIELD MANAGEMENT COMPANY, L.P. — $82.6M
- Eversept Partners, LP — $61.2M
- GEODE CAPITAL MANAGEMENT, LLC — $56.5M
Recent SNDX insider trades
- Jul 8, 2026: Metzger Michael A sold 32,375 shares ($785K)
- Jun 12, 2026: Botwood Nicholas A.J. sold 65,515 shares ($1.18M)
- Jun 1, 2026: Metzger Michael A sold 6,847 shares ($130K)
- Jun 1, 2026: Goldan Keith A. sold 1,177 shares ($22.4K)
5%+ owners
- STATE STREET CORPORATION: 6.4% (Schedule 13G, filed Aug 7, 2026)
- Vanguard Capital Management: 5.1% (Schedule 13G, filed Apr 30, 2026)
Who owns the most SNDX stock?
The largest institutional holders of Syndax Pharmaceuticals Inc in the latest 13F filings are BlackRock, Inc. (BLK) ($197M), Kynam Capital Management, LP ($176M), VANGUARD GROUP INC ($131M).
Are insiders buying or selling SNDX?
Over the last 12 months insiders bought $0 and sold $2.75M of Syndax Pharmaceuticals Inc stock on the open market (SEC Form 4).
Which famous investors own SNDX?
Izzy Englander, Two Sigma, D. E. Shaw, Renaissance Technologies, Ken Griffin.
What was SNDX's revenue last quarter?
Syndax Pharmaceuticals Inc reported revenue of $72.8M for the quarter ended June 30, 2026, with net income of −$49.4M.
Which ETFs hold SNDX?
21 ETFs and mutual funds hold it among their top 100 positions, including XBI, HRSIX, FCSGX, FBDIX.